Following Win Over Boston Scientific, Medinol Seeks Taxus Liberté Royalties
This article was originally published in The Gray Sheet
Executive Summary
Medinol says it will pursue royalties from sales of Boston Scientific's Taxus Liberté drug-eluting stent following a Sept. 21 settlement of the firms' long-running patent infringement suit
You may also be interested in...
Cordis-Medinol stent deal
Johnson & Johnson subsidiary Cordis will be the exclusive global distributor of a family of bare-metal stents developed by Israel-based Medinol, the firms announce May 23. Cordis expects to help Medinol file for approval of the first products outside the United States in the second half of 2007, and stateside in the first half of 2008. Cordis, maker of the Cypher sirolimus-eluting stent, does not currently offer a bare-metal coronary stent. The deal comes as sales of drug-eluting stents have come under pressure due to safety concerns; Johnson & Johnson also recently halted development of its Conor CoStar paclitaxel-eluting stent after the U.S. pivotal trial failed (1"The Gray Sheet" May 14, 2007, p. 9). Medinol has a history of patent litigation against its former partner, Boston Scientific, which paid Medinol $750 million in a 2005 settlement (2"The Gray Sheet" Sept. 26, 2005, p. 11)...
Cordis-Medinol stent deal
Johnson & Johnson subsidiary Cordis will be the exclusive global distributor of a family of bare-metal stents developed by Israel-based Medinol, the firms announce May 23. Cordis expects to help Medinol file for approval of the first products outside the United States in the second half of 2007, and stateside in the first half of 2008. Cordis, maker of the Cypher sirolimus-eluting stent, does not currently offer a bare-metal coronary stent. The deal comes as sales of drug-eluting stents have come under pressure due to safety concerns; Johnson & Johnson also recently halted development of its Conor CoStar paclitaxel-eluting stent after the U.S. pivotal trial failed (1"The Gray Sheet" May 14, 2007, p. 9). Medinol has a history of patent litigation against its former partner, Boston Scientific, which paid Medinol $750 million in a 2005 settlement (2"The Gray Sheet" Sept. 26, 2005, p. 11)...
Stent sparring resumes
Medinol is seeking royalties from past and future sales of Boston Scientific's Liberté and Taxus Liberté paclitaxel-eluting stent based on its assertion that the stent violates several patents. The Israeli firm filed suit with the World Intellectual Property Organization in Geneva on Feb. 21. In Sept. 2005, Boston Scientific agreed to pay its one-time partner $750 mil. to settle a long-running patent infringement suit related to its Express and first-generation Taxus stents (1"The Gray Sheet" Sept. 26, 2005, p. 11). Medinol also is pursuing patent litigation with Guidant...